Andrx Fortamet Paragraph IV Certifications
This article was originally published in The Pink Sheet Daily
FDA approval of Andrx' Fortamet (metformin extended-release) could be delayed by the company's newly filed Paragraph IV certifications against Bristol-Myers Squibb'sGlucophage XR patents
You may also be interested in...
Patients will be able to achieve optimal daily metformin dose with half as many tablets as Glucophage XR and generics. Andrx is also touting the smaller size of the pills. Fortamet will launch in May.
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.